Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司
(A joint stock company established in the People's Republic of China with limited liability)
(Stock Code: 9887)

VOLUNTARY ANNOUNCEMENT
ORAL PRESENTATION OF PHASE II CLINICAL STUDY RESULTS OF LBL-024 (OPAMTISTOMIG, PD-L1/4-1BB BISPECIFIC ANTIBODY) AT 2026 WCLC

This announcement is made by Nanjing Leads Biolabs Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform shareholders and potential investors of the Company about the latest business development of the Company.

The Company is pleased to announce that the results of the Phase II clinical study evaluating Opamtistomig (LBL-024, a PD-L1/4-1BB bispecific antibody) in combination with chemotherapy for the treatment of first-line non-small cell lung cancer (NSCLC) has been selected for oral presentation at the 2026 World Conference on Lung Cancer (WCLC) to be held from September 12 to 15, 2026. At this most influential global academic conference in the field of lung cancer, the Company will present the breakthrough efficacy of Opamtistomig in first-line NSCLC, based on a significantly expanded patient cohort relative to the previously disclosed data of 18 patients.

Early-stage of NSCLC data showed that Opamtistomig in combination with chemotherapy achieved a robust objective response rate (ORR). With extended follow-up, further improvement in response and sustained tumor shrinkage were observed across multiple subgroups, including immune-pretreated non-squamous carcinoma, first-line non-squamous carcinoma and first-line squamous cell carcinoma. The presentation at the WCLC will further demonstrate the continued high response rate and deepening tumor shrinkage of Opamtistomig across a broader patient population, with safety profile consistent with previously reported data. These results further indicate the safety breakthrough brought by the conditional activation of 4-1BB through the X-body™ platform, highlighting the clinical advantages of Opamtistomig for the treatment of first-line NSCLC.

The potential of Opamtistomig as a pan-tumor IO 2.0 cornerstone therapy has been continuously validated across three key dimensions: broad anti-tumor activity, trends towards long-term survival benefit and a safety profile comparable to PD-L1 monoclonal antibodies. Its clinical program covers 13 solid tumor indications, demonstrating first-in-class (FIC) or best-in-class (BIC) potential in NSCLC, extrapulmonary neuroendocrine carcinoma (EP-NEC), small cell lung cancer (SCLC), biliary tract cancer (BTC) and other tumor types. Clear trends towards survival benefit have been observed across multiple indications, with the potential to translate into long-term therapeutic benefits through continued follow-up. With over 600 patients enrolled, the safety profile has been favorable in both monotherapy and combination chemotherapy settings; dose escalation to 25.0 mg/kg has yet to reach the maximum tolerated dose (MTD), and no dose-limiting toxicity has been observed.

ABOUT LBL-024 (OPAMTISTOMIG)

LBL-024 is a bispecific antibody simultaneously targeting PD-L1 and 4-1BB, and is a pan-tumor IO 2.0 cornerstone therapy with potential survival benefit. Leveraging our self-developed X-body™ platform with full intellectual property rights, LBL-024 achieves conditional activation of 4-1BB, relieving PD-1/PD-L1 immunosuppression while enhancing 4-1BB regulated T-cell activation, achieving a synergistic effect in eliminating tumors. LBL-024 demonstrates a safety profile comparable to PD-1/PD-L1 inhibitors and greater potential for broad-spectrum cancer treatment, and has demonstrated first-in-class (FIC) or best-in-class (BIC) potential in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), extrapulmonary neuroendocrine carcinoma (EP-NEC) and biliary tract cancer (BTC).

As the first molecule targeting the co-stimulatory receptor 4-1BB to have reached the pivotal single-arm registrational clinical stage globally, LBL-024 has the potential to become the first drug approved for treating EP-NEC. LBL-024 has initiated clinical studies across 13 solid tumor indications in China, including one pivotal registrational clinical study and eight proof-of-concept studies, covering EP-NEC, NSCLC, SCLC, BTC, ovarian cancer (OC), esophageal squamous cell carcinoma (ESCC), hepatocellular carcinoma (HCC), gastric cancer (GC), triple-negative breast cancer (TNBC) and melanoma, among other areas with high unmet medical needs.

4-1BB, as an agonist, can reactivate apoptotic T cells and induce substantial proliferation, making it suitable for treating "cold tumors" that are resistant or unresponsive to PD-1/PD-L1 therapies. LBL-024 received the Breakthrough Therapy Designation (BTD) from CDE of the NMPA in October 2024, as well as the Orphan Drug Designation in treating neuroendocrine carcinoma (NEC) from the FDA in November 2024. In January 2026, LBL-024 received Fast Track Designation (FTD) from the FDA for the treatment of EP-NEC and Orphan Drug Designation from the European Union.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to develop, or ultimately market, LBL-024, successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司
Dr. KANG XIAOQIANG
Chairman, Executive Director and Chief Executive Officer

Nanjing, PRC, May 28, 2026

As at the date of this announcement, the board of directors of the Company comprises: (i) Dr. Kang Xiaoqiang (Chairman of the Board), Dr. Lai Shoupeng and Mr. Zuo Honggang as executive Directors; (ii) Mr. Zhang Yincheng, Dr. Chen Renhai and Dr. Wu Fenglan as non-executive Directors; and (iii) Dr. Zhang Hongbing, Mr. Du Yilong and Ms. Du Jiliu as independent non-executive Directors.